June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Oral scutellarin treatment preserves retinal structure and visual function in glaucomatous neurodegeneration
Author Affiliations & Notes
  • Jingyuan Zhu
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
    Department of Ophthalmology, Beijing Tongren Hospital, Beijing, Beijing, China
  • Anoop Sainulabdeen
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
    Department of Surgery and Radiology, College of Veterinary and Animal Sciences, Kerala Veterinary and Animal Sciences University, Thrissur, India
  • Krystal Akers
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Vishnu Adi
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Jeffrey R. Sims
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Eva Yarsky
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Yi Yan
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Yu Yu
    Pleryon Therapeutics Limited, Shenzhen, China
  • Hiroshi Ishikawa
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Christopher Kai-Shun Leung
    University Eye Center, Hong Kong Eye Hospital, Hong Kong, China
    Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China
  • Gadi Wollstein
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
  • Joel S Schuman
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
    Department of Biomedical Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States
  • Wenbin Wei
    Department of Ophthalmology, Beijing Tongren Hospital, Beijing, Beijing, China
  • Kevin Chan
    Department of Ophthalmology, NYU Langone Health, New York, New York, United States
    Department of Radiology, NYU Langone Health, New York, New York, United States
  • Footnotes
    Commercial Relationships   Jingyuan Zhu, None; Anoop Sainulabdeen, None; Krystal Akers, None; Vishnu Adi, None; Jeffrey Sims, None; Eva Yarsky, None; Yi Yan, None; Yu Yu, None; Hiroshi Ishikawa, None; Christopher Leung, None; Gadi Wollstein, None; Joel Schuman, Zeiss (P); Wenbin Wei, None; Kevin Chan, None
  • Footnotes
    Support  This work was supported in part by the National Institutes of Health R01-EY013178 and R01-EY028125 (Bethesda, Maryland); BrightFocus Foundation G2013077, G2016030 and G20190103 (Clarksburg, Maryland); State Scholarship Fund, China Scholarship Council No. 201908110347 for visiting Ph.D. student in the USA (China); Research to Prevent Blindness/Stavros Niarchos Foundation International Research Collaborators Award (New York, New York); and an Unrestricted Grant from Research to Prevent Blindness to NYU Langone Health Department of Ophthalmology.
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2386. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jingyuan Zhu, Anoop Sainulabdeen, Krystal Akers, Vishnu Adi, Jeffrey R. Sims, Eva Yarsky, Yi Yan, Yu Yu, Hiroshi Ishikawa, Christopher Kai-Shun Leung, Gadi Wollstein, Joel S Schuman, Wenbin Wei, Kevin Chan; Oral scutellarin treatment preserves retinal structure and visual function in glaucomatous neurodegeneration. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2386.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma, yet glaucoma can continue to progress despite controlled IOP. Thus, development of glaucoma neurotherapeutics remains an unmet need. Scutellarin is a flavonoid that exhibits a number of neuroprotective effects on the brain and the eye. Here, we investigated the neurobehavioral effects of oral scutellarin treatment in a novel experimental model of chronic glaucoma.

Methods : Ten adult C57BL/6J mice (Group 1) were unilaterally injected with an optically clear hydrogel into the anterior chamber to obstruct aqueous outflow and induce chronic IOP elevation. Eight other mice (Group 2) received a unilateral intracameral injection of phosphate-buffered saline only. Another eight mice (Group 3) with hydrogel-induced unilateral chronic IOP elevation also received daily oral gavage of 300 mg/kg scutellarin from 1 week before to 2 weeks after hydrogel injection. Tonometry, optical coherence tomography, and optokinetic visuobehavioral testing were performed longitudinally to monitor the IOP, total retinal thickness, visual acuity, and contrast threshold of bilateral eyes in all three groups.

Results : Intracameral hydrogel injection resulted in unilateral chronic IOP elevation with no significant IOP difference between scutellarin treatment and untreated groups (Figure 1). With scutellarin treatment, the hydrogel-injected eyes showed less retinal thinning and reduced visual behavioral deficits when compared to the untreated, hydrogel-injected eyes (Figure 2). No significant difference in retinal thickness or optokinetic measures was found in the non-injected eyes over time or between all groups.

Conclusions : Oral scutellarin treatment appeared to preserve retinal structure and visual function in experimental glaucoma induced by chronic IOP elevation. Scutellarin may be a possible candidate as a novel neurotherapeutic agent for glaucoma treatment.

This is a 2021 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×